{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:53:22Z","timestamp":1787320402710,"version":"build-2736575974"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.critrevonc.2023.104239","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T21:33:06Z","timestamp":1703021586000},"page":"104239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Brain metastases and next-generation anticancer therapies: a survival guide for clinicians"],"prefix":"10.1016","volume":"194","author":[{"given":"Angelo","family":"Dipasquale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Barigazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Losurdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Persico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Muzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piera","family":"Navarria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van den Bent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Simonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.critrevonc.2023.104239_bib1","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1093\/neuonc\/noac118","article-title":"Brain metastases: a society for neuro-oncology (SNO) consensus review on current management and future directions","volume":"24","author":"Aizer","year":"2022","journal-title":"Neuro Oncol."},{"issue":"37","key":"10.1016\/j.critrevonc.2023.104239_bib2","doi-asserted-by":"crossref","first-page":"E8717","DOI":"10.1073\/pnas.1807105115","article-title":"Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption","volume":"115","author":"Arvanitis","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104239_bib3","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104239_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104239_bib5","first-page":"329","article-title":"Concordance of PD-L1 expression and CD8+ TIL intensity between NSCLC and synchronous brain metastases","volume":"20","author":"Batur","year":"2020","journal-title":"Bosn. J. Basic Med Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104239_bib6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104239_bib7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104239_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003281","article-title":"Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab","volume":"9","author":"Brown","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104239_bib9","unstructured":"Camidge D.R., Kim H.R., Ahn M.J., et al. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial [published correction appears in J Thorac Oncol. 2022 Oct 14;:]. J Thorac Oncol. 2021;16(12):2091\u20132108. doi:\u300810.1016\/j.jtho.2021.07.035\u3009."},{"key":"10.1016\/j.critrevonc.2023.104239_bib10","doi-asserted-by":"crossref","unstructured":"D. Carbone, T. Ciuleanu, M. Cobo, et al, OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA, Journal of Thoracic Oncology, Volume 16, Issue 10, Supplement, 2021, Page S862, ISSN 1556\u20130864, https:\/\/doi.org\/10.1016\/j.jtho.2021.08.061.","DOI":"10.1016\/j.jtho.2021.08.061"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104239_bib11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clgc.2013.09.008","article-title":"A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases","volume":"12","author":"Chevreau","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2023.104239_bib12","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","article-title":"BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma","volume":"30","author":"Colombino","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib13","doi-asserted-by":"crossref","unstructured":"Cortes J., Rugo H.S., Cescon D.W., Im S.A., Yusof M.M., Gallardo C., Lipatov O., Barrios C.H., Perez-Garcia J., Iwata H., Masuda N., Torregroza Otero M., Gokmen E., Loi S., Guo Z., Zhou X., Karantza V., Pan W., Schmid P.; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022 Jul 21;387(3):217\u2013226. doi: 10.1056\/NEJMoa2202809. PMID: 35857659.","DOI":"10.1056\/NEJMoa2202809"},{"key":"10.1016\/j.critrevonc.2023.104239_bib14","doi-asserted-by":"crossref","unstructured":"Curigliano G., Mueller V., Borges V., et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis [published correction appears in Ann Oncol. 2022 Dec 21;:]. Ann Oncol. 2022;33(3):321\u2013329. doi:\u300810.1016\/j.annonc.2021.12.005\u3009.","DOI":"10.1016\/j.annonc.2021.12.005"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104239_bib15","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib16","doi-asserted-by":"crossref","unstructured":"V.\u00e9ronique Di\u00e9ras, Robert Weaver, Sara M. Tolaney, et al. Abstract PD13\u201307: Subgroup analysis of patients with brain metastases from the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in metastatic triple-negative breast cancer. Cancer Res 15 February 2021; 81 (4_Supplement): PD13\u201307. \u3008https:\/\/doi.org\/10.1158\/1538\u20137445.SABCS20-PD13\u201307\u3009.","DOI":"10.1158\/1538-7445.SABCS20-PD13-07"},{"key":"10.1016\/j.critrevonc.2023.104239_bib17","doi-asserted-by":"crossref","unstructured":"Drilon, A.E., DuBois, S.G., Farago, A.F., Geoerger, B., Grilley-Olson, J.E., Hong, D.S.,. & Doz, F.P. (2019). Activity of larotrectinib in TRK fusion cancer patients with brain metastases or primary central nervous system tumors.","DOI":"10.1200\/JCO.2019.37.15_suppl.2006"},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104239_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3244","article-title":"Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain","volume":"14","author":"Duchnowska","year":"2012","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104239_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.critrevonc.2023.104239_bib20","unstructured":"Dummer R., Queirolo P., Gerard Duhard P., et al. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study [published online ahead of print, 2023 Jul 14]. Lancet Oncol. 2023;S1470\u20132045(23)00334\u20130. doi:\u300810.1016\/S1470\u20132045(23)00334\u20130\u3009."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104239_bib21","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1200\/JCO.20.03025","article-title":"Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion\u2013positive non\u2013small-cell lung cancer","volume":"39","author":"Dziadziuszko","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104239_bib22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cncr.34016","article-title":"Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920","volume":"128","author":"Emamekhoo","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104239_bib23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104239_bib24","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.18.02218","article-title":"Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study","volume":"37","author":"Flippot","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104239_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005828","article-title":"Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG","volume":"11","author":"Franklin","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104239_bib26","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.cell.2020.04.055","article-title":"Single-cell mapping of human brain cancer reveals tumor-specific instruction of tissue-invading leukocytes","volume":"181","author":"Friebel","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104239_bib27","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104239_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.118.253708","article-title":"Brain distribution and active efflux of three panRAF inhibitors: considerations in the treatment of melanoma brain metastases","volume":"368","author":"Gampa","year":"2019","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.critrevonc.2023.104239_bib29","unstructured":"Gillespie C.S., Mustafa M.A., Richardson G.E., et al. Genomic Alterations and the Incidence of Brain Metastases in Advanced and Metastatic NSCLC: A Systematic Review and Meta-Analysis [published online ahead of print, 2023 Jun 29]. J Thorac Oncol. 2023;S1556\u20130864(23)00638-X. doi:\u300810.1016\/j.jtho.2023.06.017\u3009."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104239_bib30","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S1470-2045(20)30111-X","article-title":"Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial","volume":"21","author":"Goldberg","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2023.104239_bib31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1093\/annonc\/mdn679","article-title":"Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer","volume":"20","author":"Gow","year":"2009","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104239_bib32","first-page":"454","article-title":"An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma","volume":"72","author":"Hasanov","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"43","key":"10.1016\/j.critrevonc.2023.104239_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390614","article-title":"Neoadjuvant Immunotherapy in Melanoma: The Paradigm Shift","author":"Hieken","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104239_bib34","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.ijrobp.2020.09.020","article-title":"Patterns of disease progression after carboplatin\/etoposide + atezolizumab in extensive-stage small-cell lung cancer (ES-SCLC)","volume":"108","author":"Higgins","year":"2020","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"suppl 16","key":"10.1016\/j.critrevonc.2023.104239_bib35","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1200\/JCO.2022.40.16_suppl.9099","article-title":"Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic non\u2013small cell lung cancer (mNSCLC): treatment (tx) beyond progressive disease (PD) in platinum-pretreated patients (pts) with and without intracranial PD","volume":"40","author":"Jaane","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.critrevonc.2023.104239_bib36","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/oncolo\/oyac009","article-title":"Trastuzumab deruxtecan improves progression-free survival and intracranial response in patients with HER2-positive metastatic breast cancer and brain metastases","volume":"27","author":"Jacobson","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2023.104239_bib37","doi-asserted-by":"crossref","unstructured":"Jia K., Ren S. Neurocognitive Adverse Events of Lorlatinib: On the Way to Precise Prediction? [published correction appears in J Thorac Oncol. 2023 Feb 11;:]. J Thorac Oncol. 2023;18(1):26\u201328. doi:\u300810.1016\/j.jtho.2022.11.003\u3009.","DOI":"10.1016\/j.jtho.2022.11.003"},{"key":"10.1016\/j.critrevonc.2023.104239_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2019.101665","article-title":"Targeting the transferrin receptor for brain drug delivery","volume":"181","author":"Johnsen","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib39","doi-asserted-by":"crossref","first-page":"S397","DOI":"10.1016\/j.annonc.2020.08.473","article-title":"364O Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases","volume":"31","author":"John","year":"2020","journal-title":"Ann. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2023.104239_bib40","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.1021\/jacs.2c03944","article-title":"Target-agnostic P-glycoprotein assessment yields strategies to evade efflux, leading to a BRAF inhibitor with intracranial efficacy","volume":"144","author":"Kelly","year":"2022","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104239_bib41","article-title":"Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors","author":"Kim","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104239_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial","volume":"37","author":"Kluger","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104239_bib43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/mdu486","article-title":"Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA","volume":"26","author":"Krop","year":"2015","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104239_bib44","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/neuonc\/noab101","article-title":"Epidemiology of brain metastases and leptomeningeal disease","volume":"23","author":"Lamba","year":"2021","journal-title":"Neuro Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104239_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002995","article-title":"Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)","volume":"9","author":"Lau","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2023.104239_bib46","first-page":"OF1","article-title":"Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice VISION: Tepotinib Outcomes in METex14 Skipping NSCLC","author":"Le","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.critrevonc.2023.104239_bib47","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial","volume":"38","author":"Lin","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104239_bib48","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104239_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2023.104239_bib50","doi-asserted-by":"crossref","unstructured":"Li B.T., et al. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. Annals of Oncology 34 (Suppl. 2): S762-S763 abstr. 1321MO, Oct 2023. Available from: URL: \u3008http:\/\/doi.org\/10.1016\/j.annonc.2023.09.2354\u3009 [abstract].","DOI":"10.1016\/j.annonc.2023.09.2354"},{"issue":"5","key":"10.1016\/j.critrevonc.2023.104239_bib51","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104239_bib52","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/annonc\/mdw289","article-title":"Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104239_bib53","article-title":"Outcomes with pembrolizumab monotherapy in patients with programmed death-ligand 1-positive NSCLC with brain metastases: pooled analysis of KEYNOTE-001, 010, 024, and 042","volume":"2","author":"Mansfield","year":"2021","journal-title":"JTO Clin. Res Rep."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104239_bib54","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"New Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104239_bib55","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/jpet.112.201475","article-title":"Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases","volume":"344","author":"Mittapalli","year":"2013","journal-title":"J. Pharm. Exp. Ther."},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104239_bib56","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-017-2278-0","article-title":"Liposomal irinotecan accumulates in metastatic lesions, crosses the blood-tumor barrier (BTB), and prolongs survival in an experimental model of brain metastases of triple negative breast cancer","volume":"35","author":"Mohammad","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.critrevonc.2023.104239_bib57","doi-asserted-by":"crossref","unstructured":"Murciano-Goroff Y.R., Falcon C.J., Lin S.T., Chacko C., Grimaldi G., Liu D., Wilhelm C., Iasonos A., Drilon A. Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC Treated With Selpercatinib. J Thorac Oncol. 2023 May;18(5):620\u2013627. doi: \u300810.1016\/j.jtho.2023.01.008\u3009. Epub 2023 Jan 16. PMID: 36657661; PMCID: PMC10122712.","DOI":"10.1016\/j.jtho.2023.01.008"},{"key":"10.1016\/j.critrevonc.2023.104239_bib58","doi-asserted-by":"crossref","unstructured":"Nadal E., Rodr\u00edguez-Abreu D., Sim\u00f3 M., et al. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17\/05) [published online ahead of print, 2023 Aug 21]. J Clin Oncol. 2023;JCO2202561. doi:\u300810.1200\/JCO.22.02561\u3009.","DOI":"10.1200\/JCO.22.02561"},{"key":"10.1016\/j.critrevonc.2023.104239_bib59","doi-asserted-by":"crossref","unstructured":"Negrao M.V., Spira A.I., Heist R.S., et al. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases [published online ahead of print, 2023 Jun 16]. J Clin Oncol. 2023;JCO2300046. doi:\u300810.1200\/JCO.23.00046\u3009.","DOI":"10.1200\/JCO.23.00046"},{"issue":"61","key":"10.1016\/j.critrevonc.2023.104239_bib60","doi-asserted-by":"crossref","first-page":"103671","DOI":"10.18632\/oncotarget.22110","article-title":"Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer","volume":"8","author":"Ogiya","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104239_bib61","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/1078-0432.CCR-22-2903","article-title":"Liquid biopsy of cerebrospinal fluid enables selective profiling of glioma molecular subtypes at first clinical presentation","volume":"29","author":"Orzan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2023.104239_bib62","unstructured":"P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104239_bib63","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/neuonc\/noac144","article-title":"Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial","volume":"25","author":"P\u00e9rez-Garc\u00eda","year":"2023","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104239_bib64","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/jcm10071367","article-title":"Checkpoint inhibitors as high-grade gliomas treatment: state of the art and future perspectives","volume":"10","author":"Persico","year":"2021","journal-title":"J. Clin. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104239_bib65","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S1470-2045(13)70017-2","article-title":"CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01)","volume":"14","author":"Pestalozzi","year":"2013","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2023.104239_bib66","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2023.104239_bib67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejca.2017.07.024","article-title":"The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis","volume":"84","author":"Petrelli","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2023.104239_bib68","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/B978-0-12-811161-1.00007-4","article-title":"Brain metastases: neuroimaging","volume":"149","author":"Pope","year":"2018","journal-title":"Handb. Clin. Neurol."},{"issue":"22","key":"10.1016\/j.critrevonc.2023.104239_bib70","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1158\/1078-0432.CCR-09-1349","article-title":"The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation","volume":"15","author":"Portnow","year":"2009","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104239_bib71","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jtho.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2023.104239_bib72","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.lungcan.2013.01.019","article-title":"ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer","volume":"80","author":"Preusser","year":"2013","journal-title":"Lung Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2023.104239_bib73","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jtho.2023.04.021","article-title":"Systemic and intracranial outcomes with first-line nivolumab plus Ipilimumab in patients with metastatic NSCLC and baseline brain metastases from checkmate 227 Part 1","volume":"18","author":"Reck","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib74","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0854-5","article-title":"Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter","volume":"17","author":"Redmer","year":"2018","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104239_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/bjp.2008.260","article-title":"Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2","volume":"155","author":"R\u00e9gina","year":"2008","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.critrevonc.2023.104239_bib76","doi-asserted-by":"crossref","unstructured":"Reungwetwattana T., Nakagawa K., Cho B.C., et al. CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer [published online ahead of print, 2018 Aug 28]. J Clin Oncol. 2018;JCO2018783118. doi:\u300810.1200\/JCO.2018.78.3118\u3009.","DOI":"10.1200\/JCO.2018.78.3118"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104239_bib77","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.annonc.2021.07.016","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours","volume":"32","author":"Le Rhun","year":"2021","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104239_bib78","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104239_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100600","article-title":"The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma","volume":"7","author":"Derks","year":"2022","journal-title":"ESMO Open"},{"issue":"27","key":"10.1016\/j.critrevonc.2023.104239_bib80","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With \u2265 2 HER2-Directed Regimens: Phase III NALA Trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib81","doi-asserted-by":"crossref","unstructured":"Schmid P., Cortes J., Pusztai L., McArthur H., K\u00fcmmel S., Bergh J., Denkert C., Park Y.H., Hui R., Harbeck N., Takahashi M., Foukakis T., Fasching P.A., Cardoso F., Untch M., Jia L., Karantza V., Zhao J., Aktan G., Dent R., O'Shaughnessy J; KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb 27;382(9):810\u2013821. doi: 10.1056\/NEJMoa1910549. PMID: 32101663.","DOI":"10.1056\/NEJMoa1910549"},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104239_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00566-6","article-title":"Symptomatic melanoma CNS metastases in the TRICOTEL study","volume":"23","author":"Schmitt","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib83","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1093\/jnci\/djx273","article-title":"Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis","volume":"110","author":"Schrijver","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"21","key":"10.1016\/j.critrevonc.2023.104239_bib84","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104239_bib85","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2023.104239_bib86","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study","volume":"40","author":"Solomon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib87","doi-asserted-by":"crossref","unstructured":"Song E., Mao T., Dong H., et al. VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours [published correction appears in Nature. 2021 Feb;590(7845):E34]. Nature. 2020;577(7792):689\u2013694. doi:\u300810.1038\/s41586\u2013019-1912-x\u3009.","DOI":"10.1038\/s41586-019-1912-x"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104239_bib88","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2023.104239_bib89","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","article-title":"A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database","volume":"70","author":"Sperduto","year":"2008","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"issue":"32","key":"10.1016\/j.critrevonc.2023.104239_bib90","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2023.104239_bib91","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41571-021-00529-6","article-title":"The blood-tumour barrier in cancer biology and therapy","volume":"18","author":"Steeg","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2023.104239_bib92","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non\u2013small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2023.104239_bib93","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/annonc\/mdu133","article-title":"Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA","volume":"25","author":"Swain","year":"2014","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104239_bib94","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/S1470-2045(21)00545-3","article-title":"Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study","volume":"22","author":"Tawbi","year":"2021","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2023.104239_bib95","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jtho.2021.08.009","article-title":"Brain metastases in EGFR- and ALK-positive NSCLC: outcomes of central nervous system-penetrant tyrosine kinase inhibitors alone versus in combination with radiation","volume":"17","author":"Thomas","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib96","doi-asserted-by":"crossref","unstructured":"Tolaney S.M., Sahebjam S., Le Rhun E., et al. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer [published correction appears in Clin Cancer Res. 2021 Mar 1;27(5):1582]. Clin Cancer Res. 2020;26(20):5310\u20135319. doi:\u300810.1158\/1078\u20130432.CCR-20\u20131764\u3009.","DOI":"10.1158\/1078-0432.CCR-20-1764"},{"key":"10.1016\/j.critrevonc.2023.104239_bib97","unstructured":"Vogelbaum M.A., Brown P.D., Messersmith H., et al. Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline [published correction appears in J Clin Oncol. 2022 Apr 20;40(12):1392]. J Clin Oncol. 2022;40(5):492\u2013516. doi:\u300810.1200\/JCO.21.02314\u3009."},{"issue":"10","key":"10.1016\/j.critrevonc.2023.104239_bib98","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14\u2013mutated or MET-amplified non\u2013small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2023.104239_bib99","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"New Engl. J. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2023.104239_bib100","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1016\/j.jtho.2021.07.026","article-title":"A phase II study of osimertinib for radiotherapy-naive central nervous system metastasis from NSCLC: results for the T790M cohort of the OCEAN Study (LOGIK1603\/WJOG9116L)","volume":"16","author":"Yamaguchi","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2023.104239_bib101","doi-asserted-by":"crossref","first-page":"S1005","DOI":"10.1016\/j.annonc.2022.07.1117","article-title":"990P osimertinib for RT-na\u00efve CNS metastasis of EGFR mutation-positive NSCLC: Phase II OCEAN study (LOGIK 1603\/WJOG 9116L), part of the first-line cohort","volume":"33","author":"Yamaguchi","year":"2022","journal-title":"Ann. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282300327X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282300327X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:50:17Z","timestamp":1760903417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282300327X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":101,"alternative-id":["S104084282300327X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104239","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain metastases and next-generation anticancer therapies: a survival guide for clinicians","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104239"}}